Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma Kewalramani. Chodakewitz will remain a senior adviser to the company through early 2019.

Infectious disease and cancer company Basilea Pharmaceutica Ltd. (SIX:BSLN) said CEO Ronald Scott will retire. He is succeeded by Chief Commercial Officer David Veitch, effective April 19...